Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
The most serious risks linked to Jardiance (empagliflozin) include diabetic ketoacidosis that can occur even with normal blood sugar, severe urinary tract infections that progress to kidney infection or sepsis, and a rare but life threatening genital infection called Fournier's gangrene (necrotizing fasciitis of the perineum). Other significant concerns involve dehydration and low blood pressure with fainting, acute kidney injury, severe allergic reactions, and dangerously low blood sugar when combined with insulin or sulfonylureas, while genital yeast infections are far more common but usually less dangerous. Warning signs such as fever, pain or swelling in the genital area, fruity smelling breath, nausea with vomiting, or reduced urination need urgent medical attention, and several factors including kidney function, hydration, and other medications change your personal risk, so see below to understand more.
Because these symptoms can overlap with ordinary illness, it helps to sort out whether what you are feeling is a mild reaction or an emergency before you decide how quickly to act. A free, instant, online symptom check can help you organize your symptoms, see possible explanations, and understand whether to call your prescriber now or seek immediate care.
Last reviewed for medical accuracy: 09/26/2026
Jardiance (empagliflozin) is an SGLT2 inhibitor prescribed for adults with type 2 diabetes. By helping the kidneys remove excess glucose in urine, it can improve blood sugar control and reduce the risk of cardiovascular complications. Like all medications, Jardiance carries a range of side effects—from mild to potentially life-threatening. Below is an evidence-based overview of the worst side effects of Jardiance, what to watch for, and when to seek medical attention.
Most people tolerate Jardiance well, but a small subset may experience severe reactions. Understanding which side effects are relatively benign and which demand urgent care can help you stay safe.
• Common (usually mild to moderate):
– Genital yeast infections
– Urinary tract infections
– Increased urination, thirst
– Nausea, constipation
• Potentially serious (rare but significant):
– Diabetic ketoacidosis (DKA)
– Serious urinary tract infections (UTIs)
– Acute kidney injury
– Hypotension (low blood pressure) and dehydration
– Fournier’s gangrene
– Bone fractures, amputation risk
– Hypoglycemia (when combined with insulin or secretagogues)
– Severe skin reactions
Below, we delve into the most alarming risks.
Even with relatively normal blood sugars, Jardiance can trigger DKA—an accumulation of ketones leading to a dangerous acid–base imbalance.
Key points:
What to do:
While UTIs are common, Jardiance’s mechanism (increased glucose in urine) can raise the risk of:
Warning signs:
Immediate action:
Jardiance may reduce blood flow to the kidneys, potentially leading to acute kidney injury (AKI), especially in:
Symptoms:
Prevention and monitoring:
By promoting glucose—and with it, water—loss, Jardiance can cause low blood pressure or dehydration:
Risk factors:
Signs to watch for:
Management:
Jardiance increases sugar in the urinary tract, fueling fungal growth.
Features:
Treatment:
A very rare but life-threatening necrotizing fasciitis of the genital/perineal region.
Red flags:
Urgent steps:
Some SGLT2 inhibitors have been associated with reduced bone mineral density and increased fracture risk. Though less clear for Jardiance specifically, caution is advised in patients with:
Additionally, there has been debate over a possible heightened risk of lower-limb amputations (primarily seen with canagliflozin, a related drug). While Jardiance’s direct link remains unconfirmed, it’s wise to:
Jardiance alone rarely causes hypoglycemia. However, when combined with insulin or sulfonylureas, the risk increases.
Symptoms:
Prevention:
Extremely rare but serious dermatologic events can occur, including:
Watch for:
Action:
To lower your chances of experiencing the worst side effects:
Certain red-flag symptoms demand prompt evaluation:
If you’re ever uncertain, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker or call your doctor right away.
This overview covers the worst side effects of Jardiance but doesn’t replace personalized medical advice. Always discuss any new or concerning symptoms with your healthcare provider. If you experience life-threatening signs—such as chest pain, severe shortness of breath, or altered consciousness—call 911 or go to the nearest emergency department.
Sources: U.S. Food and Drug Administration (FDA) Prescribing Information; Peer-reviewed clinical trials and professional diabetes guidelines.
(References)
* DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015 Mar;38(3):384-93. doi: 10.2337/dc14-2364. Epub 2015 Jan 12. PMID: 25583754.
* Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.
* Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. PMID: 35228754; PMCID: PMC8938265.
* The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.
* RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol. 2023 Dec;11(12):905-914. doi: 10.1016/S2213-8587(23)00253-X. Epub 2023 Oct 18. PMID: 37865101; PMCID: PMC10957483.
* Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S, Gasior T, Jamal W, Januzzi JL, Jeong MH, Lopatin Y, Lopes RD, Merkely B, Parikh PB, Parkhomenko A, Ponikowski P, Rossello X, Schou M, Simic D, Steg PG, Szachniewicz J, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024 Apr 25;390(16):1455-1466. doi: 10.1056/NEJMoa2314051. Epub 2024 Apr 6. PMID: 38587237.
* Modzelewski KL, Pipilas A, Bosch NA. Comparative Outcomes of Empagliflozin to Dapagliflozin in Patients With Heart Failure. JAMA Netw Open. 2024 May 1;7(5):e249305. doi: 10.1001/jamanetworkopen.2024.9305. Epub 2024 May 1. PMID: 38696170; PMCID: PMC11066699.
* Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Adv Ther. 2024 Jul;41(7):2826-2844. doi: 10.1007/s12325-024-02879-w. Epub 2024 May 21. PMID: 38771475; PMCID: PMC11213770.
* Khan S, Broce A. Empagliflozin-induced Myopathy. JCEM Case Rep. 2024 Dec;2(12):luae216. doi: 10.1210/jcemcr/luae216. Epub 2024 Nov 28. PMID: 39611184; PMCID: PMC11604052.
* Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M, CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. PMID: 40470996.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.